SE422941B - Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar - Google Patents

Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar

Info

Publication number
SE422941B
SE422941B SE7603931A SE7603931A SE422941B SE 422941 B SE422941 B SE 422941B SE 7603931 A SE7603931 A SE 7603931A SE 7603931 A SE7603931 A SE 7603931A SE 422941 B SE422941 B SE 422941B
Authority
SE
Sweden
Prior art keywords
preparation
analogy procedure
benzazepine compounds
tetracyclic
pyrido
Prior art date
Application number
SE7603931A
Other languages
English (en)
Swedish (sv)
Other versions
SE7603931L (sv
Inventor
Der Burg W J Van
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE422941(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of SE7603931L publication Critical patent/SE7603931L/xx
Publication of SE422941B publication Critical patent/SE422941B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SE7603931A 1975-04-05 1976-04-02 Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar SE422941B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Publications (2)

Publication Number Publication Date
SE7603931L SE7603931L (sv) 1976-10-06
SE422941B true SE422941B (sv) 1982-04-05

Family

ID=19823518

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7603931A SE422941B (sv) 1975-04-05 1976-04-02 Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar

Country Status (17)

Country Link
US (1) US4062848A (tr)
JP (1) JPS5942678B2 (tr)
BE (1) BE840362A (tr)
CA (1) CA1076571A (tr)
CH (1) CH622261A5 (tr)
DE (1) DE2614406A1 (tr)
DK (1) DK142498B (tr)
ES (2) ES446634A1 (tr)
FI (1) FI62087C (tr)
FR (1) FR2305986A1 (tr)
GB (1) GB1543171A (tr)
HU (1) HU179401B (tr)
IE (1) IE42969B1 (tr)
LU (1) LU74680A1 (tr)
NL (2) NL189199C (tr)
SE (1) SE422941B (tr)
ZA (1) ZA761756B (tr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) * 1986-07-31 1988-02-17 Matsushita Electric Ind Co Ltd カセツト方式文字放送受信機
JPS63177670A (ja) * 1987-01-31 1988-07-21 Fujitsu General Ltd 文字放送受信装置
JPS63215179A (ja) * 1987-03-03 1988-09-07 Fujitsu General Ltd 受信装置
JPH055746Y2 (tr) * 1988-04-27 1993-02-15
RU2048469C1 (ru) * 1989-10-05 1995-11-20 Санкио Компани Лимитед Способ получения азетидинового производного или его фармацевтически приемлемой соли
EP0539164A1 (en) * 1991-10-23 1993-04-28 Sankyo Company Limited Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
DK1067934T3 (da) * 1998-04-02 2004-03-29 Akzo Nobel Nv Flydende oral opløsning omfattende det anti-depressive middel mirtazapin
AU781221B2 (en) * 1999-04-19 2005-05-12 Teva Pharmaceutical Industries Ltd. Novel synthesis and crystallization of piperazine ring-containing compounds
CN1679586A (zh) * 1999-04-19 2005-10-12 特瓦制药工业有限公司 含哌嗪环化合物的新型合成和结晶方法
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
AU777105B2 (en) 1999-04-19 2004-09-30 Teva Pharmaceutical Industries Ltd. Novel synthesis of piperazine ring
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
AU6476300A (en) * 1999-09-30 2001-05-10 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a piperazine derivative
AU6019900A (en) 1999-11-24 2001-06-04 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
AU6474200A (en) * 1999-12-13 2001-06-18 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a pyridinemethanol compound
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
DK1257278T3 (da) 2000-02-11 2006-06-12 Akzo Nobel Nv Anvendelse af mirtazapin til behandling af sövnforstyrrelser
IN190478B (tr) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6660730B2 (en) 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
IL157607A0 (en) * 2001-03-01 2004-03-28 Teva Pharma Methods for the preparation of mirtazapine intermediates
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) * 2002-10-03 2006-08-16 Zentiva, A.S. Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2005107808A2 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2575979A1 (en) * 2004-08-13 2006-02-23 Omeros Corporation Novel serotonin receptor ligands and their uses thereof
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
EP1783125A4 (en) * 2004-08-24 2008-06-18 Sumitomo Chemical Co PROCESS FOR THE PRODUCTION OF 2- (4-METHYL-2-PHENYLPIPERAZIN-1-YL) -3-CYANOPYRIDINE
JP4848704B2 (ja) * 2004-08-24 2011-12-28 住友化学株式会社 ２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US20090306046A1 (en) * 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
CA2614289A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CN1939918B (zh) * 2005-09-30 2010-09-01 北京德众万全医药科技有限公司 一种米氮平的制备方法
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
WO2007055423A1 (ja) * 2005-11-14 2007-05-18 Sumitomo Chemical Company, Limited ２－（４－メチル－２－フェニルピペラジン－１－イル）ピリジン－３－メタノールの製造方法
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
EP1993556A1 (en) * 2006-03-06 2008-11-26 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) * 2006-06-16 2008-04-01 Organon Nv Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
AU2008204800A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5192707B2 (ja) * 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
US7994314B2 (en) * 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
MX2009010967A (es) * 2007-04-11 2009-12-15 Organon Nv Un metodo para la preparacion de mirtazapina.
AR066004A1 (es) * 2007-04-11 2009-07-15 Organon Nv Un metodo para la preparacion de una benzazepina enantiomericamente pura
US20080255348A1 (en) * 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
JP2009018992A (ja) * 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
US20110201804A1 (en) * 2008-10-22 2011-08-18 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102432594B (zh) * 2011-11-28 2013-09-11 山东鲁药制药有限公司 一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) * 2013-10-21 2014-01-15 山东鲁药制药有限公司 一种米氮平的合成方法
CN104356133A (zh) * 2014-11-25 2015-02-18 南京工业大学 一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) * 2015-02-20 2018-12-05 株式会社トクヤマ １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法
KR102540021B1 (ko) 2020-12-02 2023-06-07 (주)유케이케미팜 대량 생산에 적합한 미르타자핀의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (tr) * 1966-03-12
NL7202963A (tr) * 1972-03-07 1973-09-11
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation

Also Published As

Publication number Publication date
GB1543171A (en) 1979-03-28
NL189199B (nl) 1992-09-01
SE7603931L (sv) 1976-10-06
NL7504075A (nl) 1976-10-07
BE840362A (fr) 1976-10-04
ES459348A1 (es) 1978-03-16
DK142676A (tr) 1976-10-06
LU74680A1 (tr) 1976-11-11
NL940007I2 (nl) 1994-10-17
CA1076571A (en) 1980-04-29
IE42969L (en) 1976-10-05
FR2305986B1 (tr) 1980-06-13
DK142498C (tr) 1981-07-06
DE2614406A1 (de) 1976-10-14
ES446634A1 (es) 1977-11-01
AU1236176A (en) 1977-09-29
US4062848A (en) 1977-12-13
NL189199C (nl) 1993-02-01
DK142498B (da) 1980-11-10
HU179401B (en) 1982-10-28
FI760884A (tr) 1976-10-06
JPS51122099A (en) 1976-10-25
FI62087B (fi) 1982-07-30
IE42969B1 (en) 1980-11-19
FI62087C (fi) 1982-11-10
ZA761756B (en) 1977-03-30
DE2614406C2 (tr) 1992-02-20
FR2305986A1 (fr) 1976-10-29
JPS5942678B2 (ja) 1984-10-16
NL940007I1 (nl) 1994-06-01
CH622261A5 (tr) 1981-03-31

Similar Documents

Publication Publication Date Title
SE422941B (sv) Analogiforfarande for framstellning av tetracykliska pyrido-bensazepinforeningar
SE433208B (sv) Forfarande for framstellning av fenoletrar
SE438853B (sv) Forfarande for framstellning av 2-azetidinonforeningar
DK146205C (da) Analogifremgangsmaade til fremstilling af 8alfa-ergolin-i-derivater
SE7605139L (sv) Forfarande for framstellning av vattenupptagande cellulosaetrar
SE430336B (sv) Forbettrat forfarande for framstellning av amoxicillinfrihydrat
SE427839B (sv) Analogiforfaranden for framstellning av n-aryl-n-(1-l-4-piperidinyl)-aryl-acetamider
NO139555C (no) Fremgangsmaate for fremstilling av fosgen
NO146058C (no) Analogifremgangsmaate for fremstilling av substituerte benzamider
SE443142B (sv) Forfarande for framstellning av rifamycinforeningar
SE7606116L (sv) Forfarande for framstellning av 3-fenoxidbensaldehyder
SE427841B (sv) Analogiforfarande for framstellning av tienamycinderivat
SE7604781L (sv) Forfarande for framstellning av diarylhydroxibutylaminer
SE421793B (sv) Analogiforfarande for framstellning naftyridinsubstituerade pyrrolderivat
SE420730B (sv) Analogiforfarande for framstellning av nya pentacykliska foreningar
SE404186B (sv) Forfarande for framstellning av cyklopropanolderivat
SE423814B (sv) Forfarande for framstellning av dibensofenazin- eller acenaftokinoxalinderivat
SE427840B (sv) Analogiforfarande for framstellning av tienamycinderivat
SE446726B (sv) Forfarande for framstellning av 16-metoxiprostaglandiner
SE7610637L (sv) Forfarande for framstellning av 2-alkylindaner
DK142845C (da) Analogifremgangsmaade til fremstilling af imidazolderivater
DK140476A (da) Fremgangsmade til fremstilling af trans-decalinderivater
SE7605427L (sv) Forfarande for framstellning av klorcyan
SE7603682L (sv) Forfarande for framstellning av en eteriskt substituerad monosackarid
NO149137C (no) Analogifremgangsmaate ved fremsilling av diazepin-forbindelser

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7603931-2

Format of ref document f/p: F

SPCF Application for supplementary protection certificate filed

Free format text: 9690008, 960228

NUG Patent has lapsed

Ref document number: 7603931-2

Format of ref document f/p: F

SPCG Supplementary protection certificate granted

Free format text: 9690008, 960228, EXPIRES: 20010402